Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at UCSF

Sites in San Francisco, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 2:11 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1396
Shown on this page
12
Current sort
Recently updated
Campus scope
UCSF, San Francisco, CA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within UCSF, San Francisco, CA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 1069–1080 of 1,396 matching trials with a site at UCSF, San Francisco, CA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting No phase listed Observational

A Prospective Observational Study of TPIAT

NCT03260387
Site status not listed — check the official record
View directory record Official record
Conditions
Pancreatitis, Chronic, Pancreatectomy; Hyperglycemia, Pancreatitis
Interventions
TPIAT
Procedure
Lead sponsor
University of Minnesota
Other
Eligibility
Not listed
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
12
States / cities
San Francisco, California • Chicago, Illinois • Louisville, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Nov 3, 2026, 2:11 PM EST
Recruiting Phase 3 Interventional Accepts healthy volunteers

Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial

NCT06605118
Status at this site: Recruiting
View directory record Official record
Conditions
Obstetrical Complications, Labor and Delivery Complication, Cesarean Delivery
Interventions
Azithromycin Injection, Placebo, Standard of Care Preoperative antibiotics
Drug
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
8,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Nov 3, 2026, 2:11 PM EST
Recruiting Phase 3 Interventional Accepts healthy volunteers

Aspirin Dose Escalation for the Prevention of Recurrent Preterm Delivery Trial

NCT06980025
Status at this site: Recruiting
View directory record Official record
Conditions
Preterm Delivery, Obstetrical Complications
Interventions
162mg Aspirin, 81mg Aspirin
Drug
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
14 Years and older · Female only
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Nov 3, 2026, 2:11 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Genomic Sequencing in Anatomically Normal Fetuses

NCT06211348
Status at this site: Recruiting
View directory record Official record
Conditions
Pregnant Individuals Requesting Standard Microarray
Interventions
Genomic Sequencing
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 64 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Nov 3, 2026, 2:11 PM EST
Recruiting No phase listed Observational

Registry of Patients Diagnosed With Lysosomal Storage Diseases

NCT05619900
Status at this site: Recruiting
View directory record Official record
Conditions
Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis IV A, Mucopolysaccharidosis VI, Mucopolysaccharidosis VII, Pompe Disease Infantile-Onset, Neuronopathic Gaucher Disease, Wolman Disease
Interventions
There is no intervention
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 64 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2050
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Nov 3, 2026, 2:11 PM EST
Active, not recruiting Phase 2 Interventional

FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06402331
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
FPI-2265
Drug
Lead sponsor
Fusion Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
18
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Nov 3, 2026, 2:11 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

NCT04404660
Site status not listed — check the official record
View directory record Official record
Conditions
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Interventions
AUTO1
Biological
Lead sponsor
Autolus Limited
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
23
States / cities
Duarte, California • La Jolla, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Nov 3, 2026, 2:11 PM EST
Active, not recruiting No phase listed Observational

MOON Shoulder Instability-Cohort of Patients Undergoing Operative Treatment.

NCT02075775
Site status not listed — check the official record
View directory record Official record
Conditions
Other Instability, Shoulder, Dislocations, Subluxations, Recurrent Dislocation of Shoulder Region
Interventions
Not listed
Lead sponsor
Carolyn M Hettrich
Other
Eligibility
12 Years to 99 Years
Enrollment
1,733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2042
U.S. locations
11
States / cities
San Francisco, California • Boulder, Colorado • Iowa City, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Nov 3, 2026, 2:11 PM EST
Recruiting Phase 1 Interventional

EVR and EPO for Liver Transplant Tolerance

NCT06832189
Status at this site: Recruiting
View directory record Official record
Conditions
Liver Transplant
Interventions
Everolimus, Epoetin alfa
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Nov 3, 2026, 2:11 PM EST
Active, not recruiting Phase 2 Interventional

9-ING-41 in Patients With Advanced Cancers

NCT03678883
Site status not listed — check the official record
View directory record Official record
Conditions
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
Interventions
9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin., Lomustine, Carboplatin., Nab paclitaxel., Paclitaxel., Gemcitabine - 28 day cycle, Irinotecan
Drug
Lead sponsor
Actuate Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Orange, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Nov 3, 2026, 2:11 PM EST
Active, not recruiting Phase 2 Interventional Results available

Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID

NCT06161688
Site status not listed — check the official record
View directory record Official record
Conditions
Long COVID, Post Acute Sequelae of COVID-19, Post-Acute COVID-19
Interventions
Ensitrelvir, Placebo
Drug · Other
Lead sponsor
Timothy Henrich
Other
Eligibility
18 Years to 69 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Nov 3, 2026, 2:11 PM EST
Active, not recruiting Phase 3 Interventional

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

NCT05514054
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Imlunestrant, Tamoxifen, Anastrozole, Letrozole, Exemestane
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
137
States / cities
Daphne, Alabama • Huntsville, Alabama • Mobile, Alabama + 115 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Nov 3, 2026, 2:11 PM EST

About this UCSF institution page

What this page lists
ClinicalTrials.gov records that list UCSF in San Francisco, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by University of California, San Francisco at any site, browse by condition, or browse by U.S. city.